Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
View ORCID ProfileLuis Rosero-Bixby
doi: https://doi.org/10.1101/2021.11.08.21266087
Luis Rosero-Bixby
Universidad de Costa Rica, Centro Centroamericano de Población (CCP)
Roles: Emeritus Professor

Data Availability
All data produced in the present work are contained in the manuscript (Appendix table)
Posted November 09, 2021.
Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
Luis Rosero-Bixby
medRxiv 2021.11.08.21266087; doi: https://doi.org/10.1101/2021.11.08.21266087
Subject Area
Subject Areas
- Addiction Medicine (230)
- Allergy and Immunology (507)
- Anesthesia (111)
- Cardiovascular Medicine (1256)
- Dermatology (148)
- Emergency Medicine (283)
- Epidemiology (10047)
- Gastroenterology (500)
- Genetic and Genomic Medicine (2481)
- Geriatric Medicine (239)
- Health Economics (482)
- Health Informatics (1652)
- Health Policy (756)
- Hematology (250)
- HIV/AIDS (536)
- Medical Education (255)
- Medical Ethics (75)
- Nephrology (269)
- Neurology (2301)
- Nursing (140)
- Nutrition (354)
- Oncology (1257)
- Ophthalmology (377)
- Orthopedics (134)
- Otolaryngology (226)
- Pain Medicine (158)
- Palliative Medicine (50)
- Pathology (326)
- Pediatrics (737)
- Primary Care Research (282)
- Public and Global Health (4850)
- Radiology and Imaging (846)
- Respiratory Medicine (654)
- Rheumatology (288)
- Sports Medicine (228)
- Surgery (271)
- Toxicology (44)
- Transplantation (130)
- Urology (100)